Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Esanex Inc.
• Collaborator: National Cancer Institute (NCI)

Criteria

Inclusion Criteria:

• Solid tumors or lymphoid malignancies refractory to standard therapy

• measurable disease

• recovery to Grade < 1 toxicity due to prior adverse event or chemotherapy

• no chemotherapy within 4 weeks of entering study

• Age > 18 years

• Karnofsy >= 60%

• Life expectancy > 3 months

• normal or adequate organ and marrow function

Exclusion Criteria:

• receiving other investigational agents

• brain metastases

• uncontrolled medical illness

• HIV+ receiving combination antiretroviral therapy

• significant GI disease